

# Expanded **NIPT**

## **EXPANDED SCREENING**

**Extensive Insights,  
Earlier Planning**

**NIPT-**  
noninvasive  
prenatal  
testing

AS

EARLY

AS

WEEK

10



## WHAT WILL YOU GAIN WITH AN EXPANDED NIPT SCREEN?

### MORE INSIGHTS, EARLIER

#### **Fetal chromosome abnormalities aren't limited to 3 common trisomies.**

Prenatal screening for trisomies 21, 18, and 13 has been available for over 30 years, and for over 10 years cell-free DNA (cfDNA)-based prenatal testing, also called noninvasive prenatal testing (NIPT), has been endorsed by society guidelines around the world as a screening option.

Expanded NIPT\*, also referred to as genome-wide NIPT, is an option for those patients who may be at increased risk for aneuploidy, or when a comprehensive view of all 24 chromosomes could be valuable earlier in pregnancy, without the risk of invasive procedures.

"...[F]indings other than the common trisomies are clinically relevant for pregnancy management, and...there is potential clinical utility in performing genome-wide NIPT."

- Van Opstal D, et al.<sup>1</sup>

## GAIN INSIGHTS WITH EXPANDED NIPT


NIPT gives you valuable information about the chromosomal status of the fetus as early as 10 weeks' gestation.<sup>2,3</sup>

Newer tests take advantage of next-generation sequencing (NGS) to bring a whole-genome sequencing (WGS) approach to NIPT, expanding test options beyond chromosomes 21, 18, and 13 to include rare autosomal aneuploidies (RAAs), sex chromosome aneuploidies (SCAs), and partial deletions and duplications, also referred to as copy number variations (CNVs),  $\geq 7$  Mb in size.

Traditional, targeted NIPT tests do not screen for these additional chromosomal abnormalities, which have been associated with clinically relevant outcomes such as developmental delays, intellectual disabilities, structural anomalies, and adverse pregnancy outcomes.<sup>4,5</sup>

"Basic NIPT, screening for common trisomies and SCAs, may miss ~17% of clinically relevant fetal anomalies...therefore, a noninvasive method to screen for these additional anomalies can inform patient management and care."

- Pertile, et al.<sup>6</sup>



\*Expanded NIPT does not screen for monogenic disorders.

## PREVALENCE OF RAAs AND CNVs

There is growing evidence for the clinical utility of Expanded NIPT, which enables a comprehensive view of all 24 chromosomes.

The combined screen positive rate of RAAs and CNVs early in pregnancy is estimated to be 0.44%.<sup>4,5</sup> While estimated combined screen positive rate of trisomies 21, 18, and 13 is 0.56%.<sup>7</sup>

### Why Expanded NIPT screening?

EXPANDED SCREENING						
	Common aneuploidies			SCA	Additional chromosomal conditions	
Screened condition	Trisomy 21	Trisomy 18	Trisomy 13	Sex chromosome aneuploidy	RAAs	Partial deletions and duplications ≥7 Mb
Clinical association	Down syndrome	Edwards syndrome	Patau syndrome	Turner syndrome, Klinefelter syndrome, others	Early miscarriage, fetal anomalies, growth restriction, UPD, stillbirth	Fetal anomalies, developmental delay, others
Screen positive rate, all risk <sup>6,7</sup>	0.39%	0.13%	0.04%	0.39%	0.34%*	0.1%
Total screen positive rate	0.56% <sup>7</sup>			0.41% <sup>7**</sup>	0.44% <sup>8</sup>	

Expanded NIPT may increase the overall screen positive rate, however it is only associated with nominal increase in invasive procedures.<sup>9</sup>

cfDNA Screening Observed NIPT Screen Positive Rate at FIRST Trimester. UPD=uniparental disomy; RAA=rare autosomal aneuploidy.

\*This study included only rare autosomal trisomies. The screen positive rate for all RAAs, which also includes monosomies, is expected to be marginally higher than the rate reported for rare autosomal trisomies.

\*\*0.41% includes dels/dups of sex chromosomes which VeriSeq does not screen for.

## WHY RAAs AND CNVs MATTER

A positive RAA or CNV NIPT result can represent the fetal and/or placental genome. Either way, a positive result indicates an increased risk for fetoplacental disease and has been associated with clinical relevance in half of the cases.<sup>4,9,10</sup> Even if the RAA or CNV is mosaic in nature, an abnormality within the fetus and/or placenta may manifest itself.

### Possible implications of RAA- or CNV-positive results include:



**Risk of miscarriage**—early screening may help in understanding the cause of a miscarriage and often reassures about the recurrence risk for a future pregnancy with a chromosomal abnormality.



**Risk of fetal anomalies**—RAAs and CNVs may have an adverse effect on organ and brain development, resulting in structural anomalies, developmental delays, and intellectual disability; even if the RAA is only present in the placenta, uniparental disomy in the fetus can lead to adverse effects on development.




**Risk of adverse outcomes**—if the RAA or CNV is confined to the placenta, the fetus may be chromosomally normal, but problems with the placenta may result in poor fetal growth and/or preterm labor.



## WHY RAAs AND CNVs MATTER

While ultrasound is an important screening test used in conjunction with NIPT, not all RAAs and CNVs have fetal structural anomalies visible on ultrasound. Many ultrasound findings are only visible later in pregnancy, while expanded NIPT detection of RAAs can provide relevant information earlier in gestation.<sup>11</sup>

### Clinical pathology in cases of rare aneuploides detected with NIPT:



Having insight into these chromosomal abnormalities earlier may aid you and your patient in making pregnancy and delivery management decisions.

Data compiled from multiple studies with a total of 58,513 samples screened, identifying 150 total RAAs with pregnancy outcome data available in 141 cases.<sup>1,4,12,13,14,15</sup>

CNV=copy number variation; RAA=rare autosomal aneuploidy; UPD=uniparental disomy. FGR=fetal growth restriction; PE=preeclampsia; SPTB=spontaneous preterm birth (not indicated by FGR or PE); UPD=uniparental disomy

## WHAT DOES A POSITIVE RESULT MEAN?

It is important to note that NIPT is a screening test, not a diagnostic test. Diagnostic testing is needed to confirm positive results. NIPT results should not be used as the sole basis for pregnancy management decisions.

If your patient does receive a positive NIPT result, refer them to a health care professional with appropriate expertise to discuss the reported abnormalities, what further testing and evaluations are appropriate, and potential clinical implications. Testing options can include (but are not limited to):



Detailed ultrasound evaluation to confirm fetal viability, identify possible structural anomalies in the fetus, and/or to determine if the pregnancy is at risk for complications such as intrauterine growth restriction



Diagnostic testing via chorionic villus sampling or amniocentesis to determine if the positive NIPT result is indicative of a true fetal chromosomal abnormality, fetal mosaicism, fetal uniparental disomy, or placental mosaicism



Additional specialized testing (in some cases)

### Limitations of the test:

NIPT based on cfDNA analysis from maternal blood is a screening test; it is not diagnostic. False-positive and false-negative results do occur. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision. A negative result does not eliminate the possibility that the pregnancy has a chromosomal or subchromosomal abnormality. This test does not screen for polyploidy (eg, triploidy), birth defects such as open neural tube defects, single-gene disorders, or other conditions, such as autism. There is a small possibility that the test results might not reflect the chromosomal status of the fetus, but may instead reflect chromosomal changes in the placenta (ie, confined placental mosaicism) or the mother that may or may not have clinical significance.

## VERISEQ™ NIPT SOLUTION V2: SUPPORTED BY PUBLISHED CLINICAL EXPERIENCE DATA FROM OVER 9,000 EXPANDED NIPT SAMPLES STUDIED<sup>6,8,16</sup>

To provide your patients with the best care possible, you need information from an NIPT screen you can trust. The VeriSeq™ NIPT Solution v2 combines low failure rates and strong performance making it one of the most reliable NIPT screens available.<sup>17</sup> It covers all 23 pairs of chromosomes providing the

most comprehensive view of the fetal genome for broad insights early in the pregnancy. You can test as early as 10 weeks' gestation, so you'll get results early in the pregnancy allowing more time for patient discussions and management decisions.

	Trisomy 21 Down syndrome	Trisomy 18 Edwards syndrome	Trisomy 13 Patau syndrome	RAA	Partial deletions and duplications
<b>Sensitivity</b>	>99.9%	>99.9%	>99.9%	96.4%	74.1%
<b>Specificity</b>	99.90%	99.90%	99.90%	99.80%	99.80%

Disclaimer: Sensitivity and specificity of the VeriSeq™ NIPT Solution v2 for detecting trisomies 21, 18, and 13 in a basic screen for singleton pregnancies (excluding known mosaics).

Source: VeriSeq™ NIPT Solution v2 package insert

Data on file, Illumina, Inc. 2021.

The VeriSeq NIPT Solution v2 is an in vitro diagnostic test intended for use as a screening test for the detection of genome-wide fetal genetic anomalies from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation. VeriSeq NIPT Solution v2 uses whole-genome sequencing to detect partial duplications and deletions for all autosomes and aneuploidy status for all chromosomes. The test offers an option to request the reporting of sex chromosome aneuploidy (SCA). This product must not be used as the sole basis for diagnosis or other pregnancy management decisions.

## EXTENSIVE INSIGHTS, EARLIER PLANNING

Chromosomal abnormalities occur across the genome at a collective rate that is clinically relevant. NIPT with expanded screening, powered by WGS, provides a comprehensive view of all the chromosomes in the fetal genome, yielding knowledge beyond the common aneuploidies. Now, you and your patients can obtain more insights earlier to aid in pregnancy and delivery management.

### **Is NIPT with expanded screening right for my patients?**

Expanded NIPT can be useful to identify chromosomal abnormalities early in pregnancy, in advance of subsequent ultrasound.

For example, expanded NIPT may be considered in patients with increased risk of chromosomal abnormalities, based on medical history or other clinically relevant findings.

WGS=whole-genome sequencing.





## References

1. Van Opstal D, van Maarle MC, Lichtenbelt K, et al. Origin and clinical relevance of chromosomal aberrations other than the common trisomies detected by genome-wide NIPS: results of the TRIDENT study. *Genet Med.* 2018;20(5):480-485.
2. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol.* 2012;119(5):890-901.
3. Bianchi DW, Parker RL, Wentworth J, et al; for CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med.* 2014;370(9):799-808.
4. Pertile MD, Halks-Miller M, Flowers N, et al. Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of fetoplacental disease. *Sci Transl Med.* 2017;9(405).
5. Shaffer LG, Rosenfeld JA, Dabell MP, et al. Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound. *Prenat Diagn.* 2012;32(10):986-995.
6. Pertile MD, Flowers N, Vavrek D, et al. Performance of a paired-end sequencing-based noninvasive prenatal screening test in the detection of genome-wide fetal chromosomal anomalies. *Clin Chem.* 2021;67(9):1210-1219. doi: 10.1093/clinchem/hvab067.
7. Liang D, Cram DS, Tan H, et al. Clinical utility of noninvasive prenatal screening for expanded chromosome disease syndromes. *Genet Med.* 2019;21:1998-2006.
8. Pertile MD. Genome-wide cell-free DNA-based prenatal testing for rare autosomal trisomies and subchromosomal abnormalities. In: Page-Christiaens L, Klein H-G, eds. *Noninvasive Prenatal Testing (NIPT): Applied Genomics in Prenatal Screening and Diagnosis.* London, United Kingdom: Academic Press Elsevier; 2018:97-123.
9. Kleinfinger P, Lohmann L, Luscan A, et al. Strategy for use of genome-wide non-invasive prenatal testing for rare autosomal aneuploidies and unbalanced structural chromosomal anomalies. *J Clin Med.* 2020;9(8):2466. doi: 10.3390/jcm9082466.
10. Benn P, Malvestiti F, Grimi B, Maggi F, Simoni G, Grati FR. Rare autosomal trisomies (RATs): a comparison of the detection through cell-free DNA and chorionic villus sampling [epub ahead of print]. *Ultrasound Obstet Gynecol.* 2019;54(4):458-467.
11. Ficara, A., Syngelaki, A., Hammami, A., Akolekar, R. and Nicolaides, K.H. (2020), Value of routine ultrasound examination at 35–37 weeks' gestation in diagnosis of fetal abnormalities. *Ultrasound Obstet Gynecol*, 55: 75-80. <https://doi.org/10.1002/uog.20857>
12. Lau TK, Cheung SW, Lo PS, et al. Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. *Ultrasound Obstet Gynecol.* 2014;43(3):254-264. doi:10.1002/uog.13277
13. Fiorentino F, Bono S, Pizzuti F, et al. The clinical utility of genomewide non invasive prenatal screening. *Prenat Diagn.* 2017;37(6):593-601. doi:10.1002/pd.5053 *Sci Transl Med.* 2017;9(405):eaan1240. doi:10.1126/scitranslmed.aan1240
14. Scott F, Bonifacio M, Sandow R, Ellis K, Smet ME, McLennan A. Rare autosomal trisomies: Important and not so rare. *Prenat Diagn.* 2018;38(10):765-771. doi:10.1002/pd.5325
15. Chatron N, Till M, Abel C, et al. Detection of rare autosomal trisomies through non-invasive prenatal testing: benefits for pregnancy management. *Ultrasound Obstet Gynecol.* 2019;53(1):129-130. doi:10.1002/uog.20094
16. Harasim T, Neuhann T, Behnecke A, et al. Initial Clinical Experience with NIPT for Rare Autosomal Aneuploidies and Large Copy Number Variations. *J Clin Med.* 2022; 11(2):372. <https://doi.org/10.3390/jcm11020372>
17. Data on file, Illumina, Inc 2019.

## Intended use

The VeriSeq NIPT Solution v2 is an in vitro diagnostic test intended for use as a screening test for the detection of genome-wide fetal genetic anomalies from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation. VeriSeq NIPT Solution v2 uses whole-genome sequencing to detect partial duplications and deletions for all autosomes and aneuploidy status for all chromosomes. The test offers an option to request the reporting of sex chromosome aneuploidy (SCA). This product must not be used as the sole basis for diagnosis or other pregnancy management decisions. The VeriSeq™ NIPT Solution v2 includes: the VeriSeq™ NIPT Workflow Manager v2 for the VeriSeq™ NIPT Microlab STAR, the VeriSeq™ NIPT Sample Prep Kits, and the VeriSeq™ Onsite Server v2 with the VeriSeq™ NIPT Assay Software v2. The VeriSeq™ NIPT Solution v2 is intended to be used with a next-generation sequencer.

NIPT based on cfDNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.

cfDNA=cell-free DNA.

# Expanded **NIPT**

Get access to the information you need to  
offer your patient the best care possible.

Learn more at [illumina.com](https://www.illumina.com).

M-GL-00935 v2

This material is intended for healthcare professionals only.